Parallax Volatility Advisers
ACAD icon

Parallax Volatility Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Parallax Volatility Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$719K – 2242
2023
Q2 		$719K Buy
30,000
+3,000
+11% +$66.7K ﹤0.01% 1530
2023
Q1 		$508K Buy
+27,000
New +$514K ﹤0.01% 1729
2019
Q1 		– Sell
-1,000
Closed -$16K – 2689
2018
Q4 		$16K Buy
+1,000
New +$19.4K ﹤0.01% 2430

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallax Volatility Advisers's ACAD Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 856 shares — an estimated $26.8K sold.

Parallax Volatility Advisers first reported a position in ACAD in Q2 2017 and held it in 9 quarters. The position peaked at $2.11M in Q3 2020. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Parallax Volatility Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 856 Acadia Pharmaceuticals shares in Q1 2024, an estimated $26.8K.
  • Parallax Volatility Advisers first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 9 quarters.
  • Parallax Volatility Advisers's Acadia Pharmaceuticals position peaked at $2.11M in Q3 2020.
  • 268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.